Himadri Speciality Chemical
- Market Cap
- ₹28,319 Cr
- P/E
- 33.13
Key Fundamentals
SmallcapChemicals & PetrochemicalsChemicalsPrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 22.10%
- Debt to Equity
- 0.23
- EPS (TTM)
- ₹16.94
- Book Value
- ₹101.77
- Market Cap
- ₹28,319 Cr
- P/E (TTM)
- 33.13
- P/B
- 5.51
- ROE
- 17.80%
- Dividend Yield
- 0.14%
- EBITDA
- ₹1,133 Cr
- 52W High
- ₹819.50
- 52W Low
- ₹418.50
- Day Range
- ₹548.70 – ₹566.50
- Volume
- 12,57,566
Peer Comparison
Commodities › Chemicals & Petrochemicals › Carbon Black
| 561.25 | 33.13 | 28,319 | 5.51 | 0.14% | 17.80% | 22.10% | 5,595 | 859 | |
| 270.80 | 39.25 | 10,655 | 2.63 | 1.66% | 5.56% | 7.75% | 8,860 | 271 | |
| Median 2 companies | 416.03 | 36.19 | 19,487 | 4.07 | 0.90% | 11.68% | 14.93% | 7,228 | 565 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 98/100
Category scores
- Quality
- 40
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 42
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 90
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 73
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 30
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is expected to give good quarter
- Company has delivered good profit growth of 73.7% CAGR over last 5 years
No weaknesses listed
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 5 | 4 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 8 | 0 | 2 |
Oscillators
Neutral
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 45.59
- Neutral
- MACD (12,26,9)
- −12.77
- Bullish
- SMA (50)
- 609.37
- Bearish
- SMA (200)
- 600.50
- Bearish
As of
Analyst Rating
1 of 2 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +14.71% |
|---|---|
| 5Y | +22.66% |
| 3Y | +3.76% |
| 1Y | +1.04% |
| TTM | +25.31% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | +74.25% |
| 3Y | +51.76% |
| 1Y | +36.04% |
| TTM | +31.95% |
Operating cash flow
| 10Y | +2.58% |
|---|---|
| 5Y | Turned positive |
| 3Y | +91.97% |
| 1Y | −14.54% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +8.29 pp |
|---|---|
| 5Y | +12.84 pp |
| 3Y | +11.08 pp |
| 1Y | +2.13 pp |
| TTM | −1.42 pp |
Revenue by year
| Mar 2017 | ₹1,341 Cr |
|---|---|
| Mar 2018 | ₹2,022 Cr |
| Mar 2019 | ₹2,422 Cr |
| Mar 2020 | ₹1,806 Cr |
| Mar 2021 | ₹1,679 Cr |
| Mar 2022 | ₹2,791 Cr |
| Mar 2023 | ₹4,172 Cr |
| Mar 2024 | ₹4,185 Cr |
| Mar 2025 | ₹4,613 Cr |
| Mar 2026 | ₹4,661 Cr |
Net profit by year
| Mar 2017 | ₹82.00 Cr |
|---|---|
| Mar 2018 | ₹248 Cr |
| Mar 2019 | ₹324 Cr |
| Mar 2020 | ₹205 Cr |
| Mar 2021 | ₹47.00 Cr |
| Mar 2022 | ₹39.00 Cr |
| Mar 2023 | ₹216 Cr |
| Mar 2024 | ₹411 Cr |
| Mar 2025 | ₹555 Cr |
| Mar 2026 | ₹755 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Himadri Speciality Chemical Ltd trades at ₹561.25 as of 2026-11-17 with a market cap of ₹28,319 crore, a P/E of 33.13x, and a debt-to-equity ratio of 0.16. The company has delivered strong profit compounding of 74% CAGR over five years and 25% TTM sales growth, though the stock sits roughly 31% below its 52-week high of ₹819.50.
- Exceptional long-term profit growth: compounded profit CAGR of 74% over 5 years and 44% over 10 years demonstrates sustained earnings momentum.
- TTM sales growth of 25% indicates strong top-line acceleration, well above the 3-year compounded sales growth of 4%, suggesting a recent demand pick-up.
- Very low leverage with a debt-to-equity ratio of just 0.16, providing significant balance-sheet headroom for expansion or to weather cyclical downturns.
- ROCE of 21.01% signals efficient capital deployment, indicating the business generates healthy returns on the capital invested in operations.
- ROE has improved to 18% in the last year versus a 10-year average of 14%, reflecting rising profitability and better shareholder value generation.
- Stock price CAGR of 64% over 5 years and 32% over 10 years reflects a long track record of wealth creation for shareholders.
- The stock currently trades at ₹561.25, roughly 34% above its 52-week low of ₹418.50, suggesting the price has recovered from recent lows and buying interest has returned.
- TTM profit growth of 30% continues to outpace TTM sales growth of 25%, indicating margin expansion or operating leverage in the current period.
- The stock is down approximately 31% from its 52-week high of ₹819.50, signalling that momentum has deteriorated significantly from peak levels.
- Price-to-book ratio of 5.51x is rich for a specialty chemicals business, implying the market is pricing in substantial future growth that may not materialise.
- Dividend yield of just 0.15% offers negligible income support, meaning investors are almost entirely reliant on capital appreciation.
- 3-year compounded sales growth of only 4% contrasts sharply with 47% profit growth over the same period, raising questions about whether margin gains are sustainable without top-line support.
- As a commodities-sector player, earnings are inherently cyclical and sensitive to raw material price swings, which introduces volatility risk around the current 33x P/E valuation.
- The 52-week range spans ₹418.50 to ₹819.50, a spread of roughly 96%, reflecting high price volatility that may not suit risk-averse investors.
- ROE of 15.86% as of 2026-11-17 is below the last-year figure of 18%, suggesting recent return on equity may be normalising from its peak.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Recent newsflow for Himadri Speciality Chemical is entirely procedural — a subsidiary guarantee, a management-list update, and a near-unanimous MOA alteration. There are no material headwinds or bullish catalysts in the latest cycle. The lack of negative surprises is reassuring, but investors should watch for operational or earnings updates to form a directional view.
- ₹200Cr guarantee for subsidiary Nov 7
Board approved a corporate guarantee of up to ₹200 crore for subsidiary Sturdy Niketan Private Limited and relocated its Kolkata registered office.
- Senior management list revised Oct 30
Updated senior management personnel list on October 30, 2026, including CFO Kamlesh Kumar Agarwal and CS Monika Saraswat.
- MOA alteration approved 99.99% Oct 28
Members approved alteration of the Memorandum of Association via postal ballot with 99.99% votes in favour, e-voting concluded October 27, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,005 | 1,053 | 1,177 | 1,200 | 1,137 | 1,141 | 1,135 | 1,118 | 1,071 | 1,184 | 1,288 | 1,432 | 1,691 |
| Expenses | 847 | 879 | 997 | 1,008 | 929 | 920 | 901 | 873 | 838 | 941 | 1,046 | 1,144 | 1,376 |
| Operating Profit | 158 | 174 | 180 | 192 | 208 | 221 | 233 | 245 | 233 | 243 | 242 | 288 | 315 |
| OPM % | 16% | 17% | 15% | 16% | 18% | 19% | 21% | 22% | 22% | 20% | 19% | 20% | 19% |
| Other Income | 10 | 10 | 12 | 13 | 14 | 12 | 14 | 27 | 36 | 47 | 62 | 56 | 42 |
| Interest | 16 | 21 | 14 | 13 | 11 | 12 | 9 | 16 | 15 | 16 | 17 | 22 | 28 |
| Depreciation | 12 | 13 | 13 | 13 | 13 | 15 | 14 | 15 | 17 | 18 | 19 | 21 | 22 |
| PBT | 139 | 150 | 166 | 179 | 197 | 206 | 224 | 241 | 237 | 255 | 268 | 301 | 307 |
| Tax % | 28% | 28% | 30% | 31% | 31% | 31% | 31% | 26% | 26% | 25% | 23% | 24% | 25% |
| Net Profit | 101 | 109 | 115 | 123 | 136 | 141 | 155 | 179 | 176 | 192 | 208 | 228 | 231 |
| EPS (₹) | 2.29 | 2.47 | 2.34 | 2.48 | 2.74 | 2.88 | 3.15 | 3.68 | 3.57 | 3.81 | 3.98 | 4.55 | 4.60 |
| YoY Sales growth | −5 | 1 | 14 | 26 | 13 | 8 | −4 | −7 | −6 | 4 | 14 | 28 | 58 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,437 | 1,182 | 1,341 | 2,022 | 2,422 | 1,806 | 1,679 | 2,791 | 4,172 | 4,185 | 4,613 | 4,661 | 5,595 |
| Expenses | 1,313 | 1,036 | 1,107 | 1,569 | 1,863 | 1,525 | 1,549 | 2,635 | 3,773 | 3,540 | 3,758 | 3,699 | 4,507 |
| Operating Profit | 124 | 146 | 233 | 452 | 560 | 280 | 131 | 156 | 399 | 645 | 854 | 962 | 1,087 |
| OPM % | 9% | 12% | 17% | 22% | 23% | 16% | 8% | 6% | 10% | 15% | 19% | 21% | 19% |
| Other Income | 13 | 9 | 6 | 12 | 8 | 8 | 14 | 7.22 | 27.97 | 43 | 52 | 171 | 207 |
| Interest | 103 | 111 | 82 | 70 | 71 | 55 | 33 | 36 | 66 | 64 | 45 | 64 | 84 |
| Depreciation | 59 | 67 | 33 | 33 | 34 | 39 | 47 | 50 | 51 | 50 | 55 | 68 | 79 |
| Exceptional Items | — | — | — | — | — | — | — | −24.65 | −30 | — | — | — | — |
| PBT | −24 | −23 | 125 | 361 | 462 | 194 | 65 | 53 | 280 | 574 | 806 | 1,001 | 1,131 |
| Tax % | −49% | −19% | 34% | 31% | 30% | −6% | 27% | 27% | 23% | 28% | 31% | 25% | — |
| Net Profit | −13 | −19 | 82 | 248 | 324 | 205 | 47 | 39 | 216 | 411 | 555 | 755 | 859 |
| EPS (₹) | −0.32 | −0.44 | 1.98 | 5.91 | 7.75 | 4.91 | 1.13 | 0.98 | 4.99 | 8.34 | 11.25 | 14.89 | 16.94 |
| Div. Payout % | 0% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 5% | 2% | 2% | 3% | 13% | 20% | 5% | 6% | 5% | 5% | — |
| Sales growth | 3 | −18 | 13 | 51 | 20 | −25 | −7 | 66 | 49 | 0 | 10 | 1 | 25 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 42 | 42 | 42 | 42 | 42 | 42 | 42 | 43 | 49 | 49 | 50 | 50 |
| Reserves | 750 | 837 | 988 | 1,373 | 1,590 | 1,692 | 1,751 | 1,826 | 2,237 | 2,996 | 3,672 | 4,656 | 5,085 |
| Borrowings | 1,124 | 887 | 774 | 660 | 476 | 505 | 729 | 587 | 842 | 605 | 313 | 770 | 1,160 |
| Other Liabilities | 329 | 296 | 308 | 341 | 680 | 323 | 269 | 999 | 555 | 798 | 621 | 830 | 682 |
| Total Liabilities | 2,242 | 2,062 | 2,112 | 2,416 | 2,788 | 2,562 | 2,791 | 3,454 | 3,678 | 4,449 | 4,656 | 6,306 | 6,977 |
| Fixed Assets | 1,228 | 1,180 | 1,174 | 1,178 | 1,170 | 1,475 | 1,468 | 1,546 | 1,515 | 1,534 | 1,605 | 1,942 | 2,016 |
| CWIP | 14 | 31 | 13 | 22 | 133 | 158 | 160 | 77 | 94 | 67 | 185 | 372 | 370 |
| Investments | 23 | 53 | 87 | 273 | 179 | 47 | 66 | 113 | 132 | 478 | 582 | 1,060 | 1,250 |
| Other Assets | 977 | 798 | 838 | 943 | 1,305 | 882 | 1,098 | 1,718 | 1,938 | 2,371 | 2,283 | 2,933 | 3,341 |
| Total Assets | 2,242 | 2,062 | 2,112 | 2,416 | 2,788 | 2,562 | 2,791 | 3,454 | 3,678 | 4,449 | 4,656 | 6,306 | 6,977 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 212 | 296 | 205 | 258 | 476 | 283 | −40 | 331 | 54 | 405 | 447 | 382 |
| Investing | 128 | −6 | 10 | −50 | −224 | −214 | −114 | −28 | −397 | −405 | −235 | −963 |
| Financing | −348 | −278 | −233 | −200 | −257 | −41 | 165 | −182 | 377 | 7 | −271 | 590 |
| Net Cash Flow | −7 | 12 | −18 | 8 | −6 | 28 | 11 | 121 | 34 | 7 | −60 | 10 |
| Free Cash Flow | 184 | 281 | 201 | 195 | 272 | 36 | −76 | 308 | −22 | 352 | 276 | −63 |
| CFO/EBITDA | 169 | 203 | 98 | 75 | 102 | 113 | −20 | 223 | 25 | 77 | 69 | 64 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82 | 63 | 60 | 49 | 55 | 61 | 100 | 66 | 44 | 57 | 50 | 55 |
| Inventory Days | 122 | 138 | 164 | 112 | 124 | 121 | 100 | 125 | 61 | 85 | 68 | 96 |
| Days Payable | 36 | 50 | 74 | 39 | 100 | 68 | 45 | 127 | 39 | 69 | 28 | 47 |
| Cash Conversion Cycle | 168 | 151 | 150 | 122 | 79 | 113 | 155 | 65 | 66 | 73 | 90 | 103 |
| Working Capital Days | 4 | −22 | 19 | 29 | 40 | 10 | 15 | −1 | 1 | 32 | 69 | 57 |
| ROCE % | 3% | 5% | 11% | 22% | 25% | 11% | 4% | 5% | 13% | 19% | 22% | 22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Himadri Speciality Chemical insights
65 extracted metrics across FY01–FY27.
Documents
- Q2 FY27 concall · Oct 2026Transcript PPT Recording
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Jan 2026Transcript PPT Recording
- 10 Jul 2026
- 19 Mar 2026
- 10 Sep 2025
- 31 Jul 2025
- 21 Mar 2025
Frequently Asked Questions about Himadri Speciality Chemical
What does Himadri Speciality Chemical Ltd do?
Where is Himadri Speciality Chemical Ltd (HSCL) listed?
Which sector does Himadri Speciality Chemical Ltd belong to?
What is the market capitalisation of Himadri Speciality Chemical Ltd?
What is the PE ratio of Himadri Speciality Chemical Ltd?
What is the 52-week high and low of Himadri Speciality Chemical Ltd?
Does Himadri Speciality Chemical Ltd pay dividends?
What is the Return on Equity (ROE) of Himadri Speciality Chemical Ltd?
Company Information
Himadri Speciality Chemical is primarily engaged in the manufacturing of carbon materials and chemicals. It is the No.1 coal pitch manufacturer in India and is the only company to manufacture advanced carbon material in India. It is also the largest player of Naphthalene and SNF in India.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/HSCL.md for Himadri Speciality Chemical Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.